Table 2: Adverse Events graded based on CTCAE 4.0.

 

Apatinib (N=26)

Adverse Events

Grade 1/2, n (%)

Grade 3, n (%)

Grade 4, n (%)

Hematologic

     

Leukopenia

8(30.8)

1(3.8)

    1(3.8)

Neutropenia

6(23.1)

1(3.8)

      −

Thrombocytopenia

4(15.4)

      −

Anemia

10(38.5)

2(7.7)

      −

Non-hematologic

     

Proteinuria

3(11.5)

      −

Hypertension

6(23.1)

1(3.8)

      −

Bleeding

2(7.7)

      −

Esophageal fistula

1(3.8)

      −

Fatigue

6(23.1)

1(3.8)

      −

Appetite loss

9(34.6)

      −

Nausea

7(26.9)

      −

Vomiting

5(19.2)

      −

Abdominal pain

  4(15.4)

      −

Diarrhea

6(23.1)

      −

Hand-foot skin reaction

3(11.5)

      −

Hypoproteinemia

3(11.5)

 

Hypocalcemia

2(7.7)

1(3.8)

      −

Liver function

     

Hyperbilirubinemia

4(15.4)

      −

Elavated trasaminase

5(19.2)

      −

Renal disorder

     

Creatinine clearance decrease

2(7.7)

      −

Hypothyroidism

4(15.4)

1(3.8)

Others

     

 Heart failure

1(3.8)

CTCAE: Cancer Institute’s Common Terminology Criteria for Adverse Events.